2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2277

Exon Sequencing Reveals a Significant Burden of Non-Synonymous Variants in Both SLC22A11 (OAT4) and SLC22A12 (URAT1) in European Hyperuricemic Individuals
Abstract Number: 2278

Precision of Gout Definitions for Population-Based Genetic Studies: Analysis of the UK Biobank
Abstract Number: 2279

Soluble Urate: A Direct Mediator of Bone Turnover?
Abstract Number: 2280

Monosodium Urate Crystal-Induced Inflammation Promotes Osteocyte Expression of Pro-Resorptive and Inflammatory Mediators: Implications for Erosive Gout
Abstract Number: 2281

Monosodium Urate Monohydrate (MSU) Crystals Induces Cartilage Degeneration By Accelerating Hypertrophy and Mineralization.
Abstract Number: 2282

Ferritin Levels Are Associated with Urate and Gout – a Role for Iron Metabolism in Gout ?
Abstract Number: 2283

Suppression of Monosodium Urate (MSU) Crystals-Induced Inflammatory Response By Inhibiting TGF-β Activated Kinase 1 (TAK1)
Abstract Number: 2284

Differential Effect of MSU-Crystal Induced Inflammation on Macrophage Polarization
Abstract Number: 2285

12/15-Lipoxygenase Inhibition By ML351 Protects Against Uric Acid Crystal-Induced Acute Arthritis in Mice
Abstract Number: 2286

Bioresponsive Glucocorticoid-Loaded Microparticles to Prevent Acute Gout Flares
Abstract Number: 2287

Serum Urate and Its Association with Endothelial Dysfunction in Young Adults
Abstract Number: 2288

Inflammatory Status and Serum Uric Acid Determine High-Density Lipoprotein Cholesterol Levels in a Non-Rheumatic Population
Abstract Number: 2289

Obesity and Echocardiographic Changes in the Different Stages of Gout
Abstract Number: 2290

Crystal-Proven Gout and Disease Severity Factors Influencing the Prevalence of Cardiovascular Diseases
Abstract Number: 2291

Impact of Plasma Urate and Tophaceous Burden on Inflammatory Biomarkers of Cardiovascular Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].